PR Newswire Blog | Talkmarkets | Page 1
The Authoritative Source Of News & Information

PR Newswire is the premier global provider of multimedia platforms that enable marketers, corporate communicators, sustainability officers, public affairs and investor relations officers to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution ... more

All Contributions

Latest Posts
1 to 16 of 22 Posts
1 2
Binance And Mastercard Launch Prepaid Card In Argentina To Bridge Cryptocurrencies And Everyday Purchases
​​​​​​​The country is the first in Latin America to have the product, the card is in beta phase and will be widely available in the coming weeks.
Elon Musk To Acquire Twitter
Twitter has entered into a definitive agreement to be acquired by an entity wholly owned by Elon Musk, at a 38% premium to the stock's closing price on April 1.
SciSparc To Commence A Pre-Clinical Study Using Its SCI-210 Cannabidiol Based Treatment For Epilepsy
The Company signed an agreement with The Sheba Fund for Health Services and Research at Chaim Sheba Medical Center, to examine the potential role of SCI-210 on status epilepticus.
Viatris Inc. Launches As A New Kind Of Healthcare Company, Positioned To Meet The World's Evolving Healthcare Needs
Viatris Inc. launched today following the successful combination of Mylan N.V. and Pfizer's Upjohn business.
Vistra Energy Announces Agreement To Acquire Ambit Energy
Vistra Energy announced it has entered into an agreement to acquire Ambit Energy for $475 million plus net working capital in an all-cash transaction.
Facebook To Announce First Quarter 2019 Results
Facebook, Inc. announced today that the company's first quarter 2019 financial results will be released after market close on Wednesday, April 24, 2019.
Helix TCS, Inc. Announces 176% Revenue Growth In Q3 2018
Helix TCS, Inc., a leading provider of ancillary services for the legal cannabis industry, announced its third quarter 2018 financial results today.
BiondVax Appoints CRO To Conduct Pivotal Clinical Efficacy Phase 3 Trial Of Its Novel Universal Flu Vaccine Candidate
BiondVax Pharmaceuticals developer of the Universal Flu Vaccine candidate M-001, announced today the signing of a Master Service Agreement with a contract research organization to conduct the first pivotal, clinical efficacy, Phase 3 trial of M-001.
BiondVax And European UNISEC Consortium To Host Universal Flu Vaccine Conference
BiondVax Pharmaceuticals Ltd. developer of a Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, and the European UNISEC consortium announced today they will co-host the Annual UNISEC Consortium Meeting.
BiondVax Universal Flu Vaccine Patent Granted In India
With a population of over 1.3 billion people, and high population density in some of the major cities, India is an important potential market for BiondVax and a universal flu vaccine may significantly improve public health.
BiondVax Plans Phase 3 Clinical Trial Following Receipt Of Scientific Advice From The European Medicines Agency (EMA)
BiondVax Pharmaceuticals Ltd. announced today that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) reviewed BiondVax's Phase 3 trial plan, provided advice, and allowed the Company to proceed.
BiondVax Provides Third Quarter 2017 Financial Results And Update
BiondVax Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial results for the quarter ended September 30, 2017.
BiondVax And NIH Sign Clinical Trial Agreement For A Phase 2 Trial In The U.S. With BiondVax's Universal Flu Vaccine
BiondVax Pharmaceuticals Ltd. today announced the signing of the clinical trial agreement (CTA) for a Phase 2 clinical trial with the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH).
Bed Bath & Beyond Inc. Reports Results For Fiscal 2017 Second Quarter
Net sales decrease of approximately 1.7%; comparable sales decrease of approximately 2.6%; shares down 12.5% after hours.
Guess?, Inc. Reports Second Quarter Results
GES beats on EPS but misses on revenues; stock up 15% after hours.
2breathe Unveils First Smart Device To Induce Sleep
2breathe Technologies Ltd., a pioneer in developing digital therapeutic devices, today announced that 2breathe™, a new smart, connected device tackling sleeplessness via a patented guided-breathing technology, is now publicly available.
1 to 16 of 22 Posts
1 2